Alexion Reports Second Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
UPDATE: Alexion Pharma (ALXN) Reports Q2 Revenue of $753M; Trims FY16 Outlook
July 28, 2016 6:36 AM EDT(Updated - July 28, 2016 7:06 AM EDT)
(Update notes EPS figure does not compare with consensus)
Alexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $1.13, does not compare with the analyst estimate of $1.18.
(Note: Non-GAAP diluted EPS for the second quarter 2016 was $1.13 per... More
